Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA5A | P35218 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.41 |
| ▸ | VDR | P11473 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 3/20 | 0.41 |
| ▸ | ACHE | P22303 | 3/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethanesulfonic Acid SCHEMBL5227834 | 0.93 | GAA (0.40) | GAACA1CA2CA5ACA9 | |
| SCHEMBL36225 | 0.85 | GAA (0.45) | GAACA1CA2CA5ACA9 | |
| SCHEMBL562051 | 0.83 | GAA (0.43) | GAACA1CA2CA5ACA9 | |
| SCHEMBL28963307 | 0.83 | GAA (0.43) | GAACA1CA2CA5ACA9 | |
| SCHEMBL8847449 | 0.82 | HTR6 (0.42) | CA1CA2CA5ACA9CA12 | |
| SCHEMBL31349717 | 0.81 | GAA (0.42) | GAACA1CA2CA5ACA9 | |
| SCHEMBL28500294 | 0.81 | ALDH1A1 (0.42) | GAACA1CA2CA5ACA9 | |
| SCHEMBL9418423 | 0.81 | PKM (0.52) | GAACA1CA2SMN1; SMN2KMT2A | |
| SCHEMBL6490 | 0.81 | GAA (0.59) | GAACA1CA2CA5ACA9 | |
| SCHEMBL9418416 | 0.81 | TDP1 (0.46) | GAACA1CA2CA5ACA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11707538-B2 | Methods and devices to generate [F-18]triflyl fluoride and other [F-18] sulfonyl fluorides | WASHINGTON UNIVERSITY (US) | 2023-07-25 | — | — | US | claimed |
| US-11242314-B2 | Synthesizing pet tracers using [F-18]sulfonyl fluoride as a source of [F-18]fluoride | WASHINGTON UNIVERSITY (US) | 2022-02-08 | — | — | US | claimed |
| CN-113735813-A | Photocatalytic synthesis method of 3-trifluoromethylselenocyclochromone compound | 湖南科技学院 | 2021-12-03 | — | — | CN | claimed |
| US-20200197422-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES, INC. | 2020-06-25 | — | — | US | claimed |
| CN-111233869-A | Novel compound for preparing Rudexilvir key intermediate and preparation method thereof | 杭州新博思生物医药有限公司 | 2020-06-05 | — | — | CN | claimed |
| US-5905163-A | REDUCTION OF CYANO GROUP BY CATALYTIC HYDROGENATION | MONSANTO COMPANY (US) | 1999-05-18 | — | — | US | claimed |
| EP-4591935-A2 | METHODS FOR THE PREPARATION OF RIBOSIDES | Gilead Sciences, Inc. (US) | 2025-07-30 | — | — | EP | disclosed |
| CN-113549120-B | Method for preparing ribonucleoside | 吉利德科学公司 | 2025-04-29 | — | — | CN | disclosed |
| EP-4036099-B1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES INC (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20240409575-A1 | METHODS OF PREPARING 1'-CYANO NUCLEOSIDES | GILEAD SCIENCES, INC. | 2024-12-12 | — | — | US | disclosed |
| CN-118994170-A | Process for preparing 1' -cyanonucleosides | 吉利德科学公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-118812607-A | Method for preparing ribonucleoside | 吉利德科学公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-115298181-B | Process for preparing 1' -cyanonucleosides | 吉利德科学公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-1290275-A | Catalyst and process for polymerization of cycloolefin | GOODRICH CO B F (US) | 2001-04-04 | — | — | CN | disclosed |
| US-5905163-A | REDUCTION OF CYANO GROUP BY CATALYTIC HYDROGENATION | MONSANTO COMPANY (US) | 1999-05-18 | — | — | US | disclosed |
| EP-0546056-B1 | MEMBRANES HAVING SELECTIVE PERMEABILITY | UNIV CALIFORNIA (US) | 1996-04-24 | — | — | EP | disclosed |
| US-5358556-A | Separation of gas mixtures | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1994-10-25 | — | — | US | disclosed |
| EP-0546056-A1 | MEMBRANES HAVING SELECTIVE PERMEABILITY. | UNIV CALIFORNIA (US) | 1993-06-16 | — | — | EP | disclosed |
| US-5096586-A | Doped and undoped with acids and bases | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1992-03-17 | — | — | US | disclosed |
| WO-1992003217-A1 | MEMBRANES HAVING SELECTIVE PERMEABILITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1992-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240409575-A1 | METHODS OF PREPARING 1'-CYANO NUCLEOSIDES | PNP, TYMP, DUT | GAA 271/4885CA1 2424/4885CA2 2966/4885 |
| US-11242314-B2 | Synthesizing pet tracers using [F-18]sulfonyl fluoride as a source of [F-18]fluoride | STX18, GPR119, SLC5A1 | GAA 268/4885CA1 881/4885CA2 818/4885 |
| US-11707538-B2 | Methods and devices to generate [F-18]triflyl fluoride and other [F-18] sulfonyl fluorides | STX18, PFAS, FLI1 | GAA 142/4885CA1 1601/4885CA2 1542/4885 |
| US-20200197422-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | PRPS1, PRPF4, PRPF31 | GAA 343/4885CA1 4736/4885CA2 4682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.